Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer - Takeaways - MDSpire

Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer

  • By

  • Kristina L. Tatum

  • Bassam Dahman

  • Aniyah Stevenson

  • Sarah E. Williford

  • J. Brian Cassel

  • Hua Zhao

  • Jie Shen

  • Kandace P. McGuire

  • Obinna Diala

  • Racheal Oladimeji

  • W. Greg Hundley

  • Bernard F. Fuemmeler

  • May 11, 2026

  • 0 min

Share

  • 1

    Breast cancer is the most common cancer among women in the US, contributing to over 30% of all cancer cases.

  • 2

    Obesity and type 2 diabetes are linked to poor breast cancer outcomes, including reduced survival and increased recurrence.

  • 3

    GLP-1 receptor agonists, used for diabetes and weight loss, may have potential benefits for breast cancer survival and recurrence.

  • 4

    This study analyzed EHR data from 841,831 breast cancer patients to assess the impact of GLP-1 RA use on mortality and recurrence.

  • 5

    Propensity score matching was employed to balance cohorts, ensuring reliable comparisons of outcomes related to GLP-1 RA use.

Original Source(s)

Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer

  • by Kristina L. Tatum, Bassam Dahman, Aniyah Stevenson, Sarah E. Williford, J. Brian Cassel, Hua Zhao, Jie Shen, Kandace P. McGuire, Obinna Diala, Racheal Oladimeji, W. Greg Hundley, Bernard F. Fuemmeler

  • May 11, 2026

Related Content

Peripheral blood monocytes could be associated with brain metastasis and affect patient prognosis in breast cancer: a retrospective study

Multi-parametric MRI habitat radiomics with interpretable machine learning for early prediction of axillary lymph node metastasis in triple-negative breast cancer

Diagnosis and treatment of breast cancer metastasis to thyroid: a case report and literature review